There was a time when CSL Ltd (ASX: CSL) could almost do no wrong in the eyes of investors. But that now feels like a very long time ago. At the time of writing, the CSL share price is down 1.77% to ...

CSL Limited, usually the bluest of blue-chip stocks on the ASX, has incinerated nearly $56 billion of its sharemarket value in the last 12 months. Now, the plasma and vaccines giant’s chair Brian ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

We look into the body’s circulatory systems. By Sam Sifton I’m the host of The Morning. We’ve long known about two systems in the human body that circulate fluids. A physician in Italy observed the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Melbourne-based company will ...

Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee. CSL will expand its current footprint ...

BRADLEY, Ill. -- Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions. Eli ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

SYDNEY--Australia-based pharmaceutical company CSL posted a steep decline in fiscal first-half profit, reflecting government policy changes, shifting public attitudes toward vaccines and one-off costs ...